Skip to main content
. 2021 Jun 26;9(4):e00786. doi: 10.1002/prp2.786

FIGURE 7.

FIGURE 7

Proposed mechanism by which eribulin exerts antiproliferative effects through modulating stathmin dynamics in breast cancer cell. Eribulin phosphorylates stathmin by activating the PKA and CaMKII pathways, and by downregulating PP2A level in breast cancer cells. Overexpression of stathmin potentiates the antiproliferative effects of eribulin